Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis
Authors:
- 1 February 2017
- journal article
- review article
- Published by Elsevier in Neuropharmacology
- Vol. 113, 618-626
Abstract
No abstract availableKeywords
Funding Information
- University College Cork
- Trinity College Dublin
This publication has 127 references indexed in Scilit:
- Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosisThe Pharmacogenomics Journal, 2012
- Inflammatory Cortical Demyelination in Early Multiple SclerosisNew England Journal of Medicine, 2011
- Regulation of the severity of neuroinflammation and demyelination by TLR‐ASK1‐p38 pathwayEMBO Molecular Medicine, 2010
- Toll-like Receptor 2 Signaling in CD4+ T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune DiseaseImmunity, 2010
- Role of the innate immune system in the pathogenesis of multiple sclerosisJournal of Neuroimmunology, 2010
- Multiple sclerosisThe Lancet, 2008
- Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid ReceptorsBritish Journal of Pharmacology, 2007
- Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammationNeuroscience, 2007
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- Toll-like receptors and innate immunityNature Reviews Immunology, 2001